JP2020115783A - 血糖値上昇抑制作用を有する発酵乳 - Google Patents
血糖値上昇抑制作用を有する発酵乳 Download PDFInfo
- Publication number
- JP2020115783A JP2020115783A JP2019009905A JP2019009905A JP2020115783A JP 2020115783 A JP2020115783 A JP 2020115783A JP 2019009905 A JP2019009905 A JP 2019009905A JP 2019009905 A JP2019009905 A JP 2019009905A JP 2020115783 A JP2020115783 A JP 2020115783A
- Authority
- JP
- Japan
- Prior art keywords
- fermented milk
- blood glucose
- eps
- glucose level
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015140 cultured milk Nutrition 0.000 title claims abstract description 181
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 201000001421 hyperglycemia Diseases 0.000 title abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 39
- 230000007423 decrease Effects 0.000 claims abstract description 33
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 30
- 230000037182 bone density Effects 0.000 claims abstract description 30
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 13
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims description 199
- 210000004369 blood Anatomy 0.000 claims description 198
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 172
- 239000008103 glucose Substances 0.000 claims description 172
- 206010012601 diabetes mellitus Diseases 0.000 claims description 57
- 235000000346 sugar Nutrition 0.000 claims description 34
- 150000004676 glycans Chemical class 0.000 claims description 13
- 229920001282 polysaccharide Polymers 0.000 claims description 13
- 239000005017 polysaccharide Substances 0.000 claims description 13
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 abstract description 12
- 229920002444 Exopolysaccharide Polymers 0.000 abstract 2
- 238000000034 method Methods 0.000 description 28
- 230000037396 body weight Effects 0.000 description 25
- 235000013336 milk Nutrition 0.000 description 24
- 239000008267 milk Substances 0.000 description 24
- 210000004080 milk Anatomy 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 229930006000 Sucrose Natural products 0.000 description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 20
- 239000005720 sucrose Substances 0.000 description 20
- 208000001132 Osteoporosis Diseases 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 235000020183 skimmed milk Nutrition 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000001954 sterilising effect Effects 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000007774 longterm Effects 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
- 239000007858 starting material Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000004153 glucose metabolism Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000000291 postprandial effect Effects 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 235000013618 yogurt Nutrition 0.000 description 9
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 8
- 239000004375 Dextrin Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 235000019425 dextrin Nutrition 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 229960002632 acarbose Drugs 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 235000005686 eating Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 238000002224 dissection Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 4
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000013118 diabetic mouse model Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 208000005156 Dehydration Diseases 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 108090000573 Osteocalcin Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 235000008476 powdered milk Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 108010054770 glucose dehydrogenase (pyrroloquinoline-quinone) Proteins 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000012174 carbonated soft drink Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 238000007601 warm air drying Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Health & Medical Sciences (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Dairy Products (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)及びストレプトコッカス・サーモフィラス(Streptococcus thermophilus)を使用した、30mg/kg以上の菌体外多糖(EPS)を含有する、血糖値上昇抑制用の発酵乳。
[2]血糖値上昇抑制及び骨密度低下抑制用の、上記[1]に記載の発酵乳。
[3]糖尿病に罹患しているか又はその発症のリスクがある対象のための、上記[1]又は[2]に記載の発酵乳。
[4]ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカスが、ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)OLL1247株(受託番号NITE BP-01814)である、上記[1]〜[3]のいずれかに記載の発酵乳。
[5]ストレプトコッカス・サーモフィラスが、ストレプトコッカス・サーモフィラス(Streptococcus thermophilus)OLS3078株(受託番号NITE BP-01697)である、上記[1]〜[4]のいずれかに記載の発酵乳。
[6]上記[1]〜[5]のいずれかに記載の発酵乳を含む、血糖値上昇抑制用の食品。
[7]上記[1]〜[5]のいずれかに記載の発酵乳を含む、血糖値上昇抑制用の飼料。
[8]血糖値上昇抑制及び骨密度低下抑制用の、上記[6]に記載の食品。
[9]血糖値上昇抑制及び骨密度低下抑制用の、上記[7]に記載の飼料。
[10]糖尿病に罹患しているか又はその発症のリスクがある対象のための、上記[6]又は[8]に記載の食品。
[11]糖尿病に罹患しているか又はその発症のリスクがある対象のための、上記[7]又は[9]に記載の飼料。
本発明は、ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)及びストレプトコッカス・サーモフィラス(Streptococcus thermophilus)をスターターとして用いた乳の発酵により得られる、菌体外多糖(extracellular polysaccharide;EPS)を好ましくは高濃度で含有する発酵乳が、血糖値上昇抑制作用を有するという知見に基づく。本発明はまた、そのようなEPSを好ましくは高濃度で含有する発酵乳を長期摂取することにより、糖代謝が改善し、また骨密度低下が抑制されるという知見に基づく。本発明は、ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)及びストレプトコッカス・サーモフィラス(Streptococcus thermophilus)を用いて調製される、菌体外多糖(EPS)を含有する血糖値上昇抑制用及び/又は骨密度低下抑制用の発酵乳を提供する。
一般的な発酵乳と比較して増加したEPS含量を有する高EPS発酵乳を、以下のようにして調製した。スターターとしてラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)OLL1247株(受託番号NITE BP-01814)とストレプトコッカス・サーモフィラス(Streptococcus thermophilus)OLS3078株(受託番号NITE BP-01697)を用いた。表1に示す配合比でスターター以外の原料を混合して調製したヨーグルトベースを、95℃に達温させ殺菌した後、スターター(OLL1247株とOLS3078株を同菌数含む)を3重量%添加し、43℃で3〜5時間発酵させた。発酵終了後、氷冷下で撹拌冷却することでヨーグルトをスムージングさせ、それにより脱脂粉乳ベースの高EPS発酵乳及び低EPS発酵乳を調製した。
実施例1で調製した高EPS発酵乳を用いて、以下のように糖負荷試験により血糖値推移に及ぼす影響を調べた。
- 水群(陰性対照)(n=8)
- 高EPS発酵乳群(n=6)
- 難消化性デキストリン(IDex)群(陽性対照)(n=6)
高EPS発酵乳との比較のため、低EPS発酵乳を、スターター以外は実施例1と同様の手順及び表1に示す配合比に従って調製した。対照発酵乳のスターターとしてはラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus; L. bulgaricus)OLL1150株とストレプトコッカス・サーモフィラス(Streptococcus thermophilus; S. thermophilus)OLS3078株(受託番号NITE BP-01697)を用いた。
高EPS発酵乳として実施例1で調製したものを用いた。
低EPS発酵乳及び高EPS発酵乳の特性比較を表3に示す。
- 低EPS発酵乳群(n=15)
- 高EPS発酵乳群(n=15)
本実施例では、高EPS発酵乳をショ糖と共に投与し、門脈血の血糖値(血中グルコース濃度)を測定して対照と比較することにより、高EPS発酵乳がショ糖の吸収に及ぼす影響を検討した。門脈血血糖値は腸からのグルコース吸収量を直接反映することが知られている。
- 低EPS発酵乳群
- 高EPS発酵乳群
(i) 脱脂粉乳ベースの高EPS発酵乳及び低EPS発酵乳の調製
脱脂粉乳ベースの高EPS発酵乳の調製のために、スターターとしてラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)OLL1247株(受託番号NITE BP-01814)とストレプトコッカス・サーモフィラス(Streptococcus thermophilus)OLS3078株(受託番号NITE BP-01697)を用いた。
II型糖尿病モデルマウスであるdb/dbマウス(雄、5週齢、n=40)、及び健常+m/+mマウス(n=8)を日本クレア社から入手し、標準精製飼料AIN-93M(日本クレア社;表6)の給与下で1週間飼育することにより馴化した後、評価試験に用いた。
- 対照群(db/dbマウス、高スターチ食)
- 脱脂粉乳群(db/dbマウス、脱脂粉乳食)
- 低EPS発酵乳群(db/dbマウス、低EPS発酵乳食)
- 高EPS発酵乳群(db/dbマウス、高EPS発酵乳食)
- アカルボース群(db/db、アカルボース食;陽性対照)
各群のマウスに、表6に従って調製した試験飼料を8週間にわたり自由摂取させた。
Claims (11)
- ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)及びストレプトコッカス・サーモフィラス(Streptococcus thermophilus)を使用した、30mg/kg以上の菌体外多糖(EPS)を含有する、血糖値上昇抑制用の発酵乳。
- 血糖値上昇抑制及び骨密度低下抑制用の、請求項1に記載の発酵乳。
- 糖尿病に罹患しているか又はその発症のリスクがある対象のための、請求項1又は2に記載の発酵乳。
- ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカスが、ラクトバチルス・デルブルッキー・サブスピーシーズ・ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)OLL1247株(受託番号NITE BP-01814)である、請求項1〜3のいずれか1項に記載の発酵乳。
- ストレプトコッカス・サーモフィラスが、ストレプトコッカス・サーモフィラス(Streptococcus thermophilus)OLS3078株(受託番号NITE BP-01697)である、請求項1〜4のいずれか1項に記載の発酵乳。
- 請求項1〜5のいずれか1項に記載の発酵乳を含む、血糖値上昇抑制用の食品。
- 請求項1〜5のいずれか1項に記載の発酵乳を含む、血糖値上昇抑制用の飼料。
- 血糖値上昇抑制及び骨密度低下抑制用の、請求項6に記載の食品。
- 血糖値上昇抑制及び骨密度低下抑制用の、請求項7に記載の飼料。
- 糖尿病に罹患しているか又はその発症のリスクがある対象のための、請求項6又は8に記載の食品。
- 糖尿病に罹患しているか又はその発症のリスクがある対象のための、請求項7又は9に記載の飼料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019009905A JP7267020B2 (ja) | 2019-01-24 | 2019-01-24 | 血糖値上昇抑制作用を有する発酵乳 |
CN202010060023.7A CN111466439A (zh) | 2019-01-24 | 2020-01-19 | 具有血糖值上升抑制作用的发酵乳 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019009905A JP7267020B2 (ja) | 2019-01-24 | 2019-01-24 | 血糖値上昇抑制作用を有する発酵乳 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020115783A true JP2020115783A (ja) | 2020-08-06 |
JP7267020B2 JP7267020B2 (ja) | 2023-05-01 |
Family
ID=71765420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019009905A Active JP7267020B2 (ja) | 2019-01-24 | 2019-01-24 | 血糖値上昇抑制作用を有する発酵乳 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7267020B2 (ja) |
CN (1) | CN111466439A (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7089818B1 (ja) | 2022-01-11 | 2022-06-23 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
JP7190773B1 (ja) | 2021-12-22 | 2022-12-16 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112662717A (zh) * | 2021-01-28 | 2021-04-16 | 华南理工大学 | 一种鼠李糖乳杆菌胞外多糖及其制备方法与应用 |
CN115137757A (zh) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | 一种辅助降血糖的益生菌组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016182049A (ja) * | 2015-03-25 | 2016-10-20 | フジッコ株式会社 | 豆乳発酵促進組成物および豆乳発酵物の製造方法 |
WO2017057319A1 (ja) * | 2015-09-30 | 2017-04-06 | 株式会社明治 | 乳酸菌スターターの調製方法及び発酵乳の製造方法 |
WO2017146213A1 (ja) * | 2016-02-24 | 2017-08-31 | 日東薬品工業株式会社 | ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物 |
JP2017153458A (ja) * | 2016-03-04 | 2017-09-07 | フジッコ株式会社 | 大豆粉を使用した乳酸菌発酵物の製造方法 |
WO2017164298A1 (ja) * | 2016-03-24 | 2017-09-28 | 株式会社 明治 | 紅斑生成抑制用組成物ならびにその使用方法およびその製造方法、紅斑の生成を抑制する方法、乳酸菌産生物 |
WO2018169027A1 (ja) * | 2017-03-16 | 2018-09-20 | 株式会社明治 | フィトケミカル吸収促進剤 |
WO2018181455A1 (ja) * | 2017-03-29 | 2018-10-04 | 株式会社明治 | 乳酸菌スターター及び発酵乳の製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4580542B2 (ja) * | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
CN102965318B (zh) * | 2012-11-26 | 2014-03-12 | 吉林省农业科学院 | 一株产胞外多糖的嗜热链球菌及其应用 |
WO2015137423A1 (ja) * | 2014-03-14 | 2015-09-17 | 株式会社 明治 | 発酵乳を得るためのスタータ,低脂肪・無脂肪アイスクリーム様食品,及び低脂肪・無脂肪アイスクリーム様食品の製造方法 |
CN108148775B (zh) * | 2017-12-26 | 2021-09-07 | 光明乳业股份有限公司 | 一株高产胞外多糖的嗜热链球菌、保存培养方法及利用该嗜热链球菌制备发酵乳的方法 |
-
2019
- 2019-01-24 JP JP2019009905A patent/JP7267020B2/ja active Active
-
2020
- 2020-01-19 CN CN202010060023.7A patent/CN111466439A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016182049A (ja) * | 2015-03-25 | 2016-10-20 | フジッコ株式会社 | 豆乳発酵促進組成物および豆乳発酵物の製造方法 |
WO2017057319A1 (ja) * | 2015-09-30 | 2017-04-06 | 株式会社明治 | 乳酸菌スターターの調製方法及び発酵乳の製造方法 |
WO2017146213A1 (ja) * | 2016-02-24 | 2017-08-31 | 日東薬品工業株式会社 | ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物 |
JP2017153458A (ja) * | 2016-03-04 | 2017-09-07 | フジッコ株式会社 | 大豆粉を使用した乳酸菌発酵物の製造方法 |
WO2017164298A1 (ja) * | 2016-03-24 | 2017-09-28 | 株式会社 明治 | 紅斑生成抑制用組成物ならびにその使用方法およびその製造方法、紅斑の生成を抑制する方法、乳酸菌産生物 |
WO2018169027A1 (ja) * | 2017-03-16 | 2018-09-20 | 株式会社明治 | フィトケミカル吸収促進剤 |
WO2018181455A1 (ja) * | 2017-03-29 | 2018-10-04 | 株式会社明治 | 乳酸菌スターター及び発酵乳の製造方法 |
Non-Patent Citations (3)
Title |
---|
HIROAKI TANAKA、ET.AL: "Characteristics of Bone Strength and Metabolism in Type2 Diabetic Model Nagoya Shibata Yasuda Mice", BIOL. PHARM. BULL., vol. 41, no. 10, JPN6022050878, 2018, pages 1567 - 1573, ISSN: 0004936647 * |
MARI MORI, ET.AL: "Beneficial Effect of Viscous Fermented Milk on Blood Glucose and Insulin Responses to Carbohydrates", GERIATRICS, vol. Chapter:10, JPN6022050876, 2012, pages 141 - 152, ISSN: 0004936645 * |
荒井威吉ほか: "高齢者の骨密度と牛乳・ヨーグルト・チーズの摂取量との相関について", 新潟青陵大学短期大学部研究報告, vol. 第45号, JPN6022050877, April 2015 (2015-04-01), pages 121 - 126, ISSN: 0004936646 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7190773B1 (ja) | 2021-12-22 | 2022-12-16 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
JP2023093232A (ja) * | 2021-12-22 | 2023-07-04 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
JP7089818B1 (ja) | 2022-01-11 | 2022-06-23 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
JP2023102164A (ja) * | 2022-01-11 | 2023-07-24 | オハヨー乳業株式会社 | 乳酸菌スターター及びそれを用いて得られる発酵乳 |
Also Published As
Publication number | Publication date |
---|---|
CN111466439A (zh) | 2020-07-31 |
JP7267020B2 (ja) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7267020B2 (ja) | 血糖値上昇抑制作用を有する発酵乳 | |
AU719204B2 (en) | Anti-stress drugs and functional foods having anti-stress effects | |
Mckinley | The nutrition and health benefits of yoghurt | |
AU2008222007B2 (en) | Agent for reducing visceral fat | |
JP2021527104A (ja) | サトウキビ由来の全植物繊維抽出物を使用した炎症性腸疾患の治療のための製剤 | |
WO2012014971A1 (ja) | メタボリックシンドローム改善効果を有する乳酸菌 | |
JP7158761B2 (ja) | 乳酸菌株の混合物を含むスターターカルチャー、そのようなスターターカルチャーを使用して製造された発酵製品、及びその発酵製品の使用 | |
JP6923883B2 (ja) | 栄養状態改善に使用するための組成物 | |
US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
EP3285785B1 (en) | Composition for reducing intestinal gas production | |
JP2019535828A (ja) | ギ酸生成能に優れた菌株を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物 | |
KR101545551B1 (ko) | 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물 | |
TW201705969A (zh) | 新穎馬利乳酸桿菌aps1及其用途 | |
JP2023175938A (ja) | 糖代謝改善用組成物 | |
JPWO2012073924A1 (ja) | 子宮内膜症の予防及び/又は改善剤及びこれを含んでなる飲食品組成物 | |
TW201132286A (en) | Novel lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof | |
JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
JP2013538827A (ja) | 腎機能を増強させるための組成物および方法 | |
CN111543639A (zh) | 用以保护肝脏的含乳酸菌菌株的食品组合物以及医药组合物 | |
Rugji et al. | Prebiotic effect of D-allulose and β-glucan on whey beverage with Bifidobacterium animalis and investigation of some health effects of this functional beverage on rats | |
JP5089942B2 (ja) | 内臓脂肪蓄積抑制剤 | |
JPWO2018174125A1 (ja) | 脂質代謝改善用組成物 | |
WO2006093013A1 (ja) | 血清コレステロール低下材およびその製造方法、ならびに血清コレステロール低下作用を有する食品組成物および医薬組成物 | |
Kairey et al. | The effects of kefir consumption on human health: a systematic review of randomized controlled trials | |
Muneer et al. | Nutritional, health-promoting properties and antioxidant activity of Yemeni fermented milk (Laban) and A Laban-Pulicaria jaubertii mixture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220120 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7267020 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |